ABEONA THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
ABEO$2.46-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for 2023 and 2022
(In thousands)
| For the years ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(54,188) | $(39,696) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 2,288 | 3,093 |
| Stock-based compensation expense | 4,768 | 3,051 |
| Change in fair value of warrant liabilities | 11,695 | (11,383) |
| Non-cash impairment of licensed technology | — | 1,355 |
| Non-cash loss/(gain) on operating lease right-of-use assets | (1,065) | 2,511 |
| Non-cash impairment of construction-in-progress | — | 1,792 |
| Accretion and interest on short-term investments | (93) | (380) |
| Amortization of right-of-use lease assets | 910 | 1,484 |
| Non-cash interest | 417 | 736 |
| Loss on disposal of property and equipment | 47 | 138 |
| Gain on lease termination | — | (292) |
| Change in operating assets and liabilities: | ||
| Accounts receivable | — | 3,000 |
| Other receivables | (2,041) | (188) |
| Prepaid expenses and other current assets | (155) | 1,953 |
| Other assets | (234) | 125 |
| Accounts payable and accrued expenses | 2,041 | (4,108) |
| Lease liabilities | (1,196) | (1,382) |
| Change in payable to licensor | — | (5,000) |
| Other current liabilities | (203) | (292) |
| Net cash used in operating activities | (37,009) | (43,483) |
| Cash flows from investing activities: | ||
| Capital expenditures | (331) | (130) |
| Proceeds from disposal of property and equipment | 204 | 1,734 |
| Purchases of short-term investments | (51,636) | (78,212) |
| Proceeds from maturities of short-term investments | 51,971 | 52,644 |
| Net cash provided by (used in) investing activities | 208 | (23,964) |
| Cash flows from financing activities: | ||
| Proceeds from ATM sales of common stock, net of issuance costs | 14,408 | 12,839 |
| Proceeds from sales of common stock under direct placement offering, net of issuance costs | 22,981 | — |
| Proceeds from sales of common stock and warrants in private offering, net of issuance costs | — | 34,121 |
| Proceeds from net settlement of restricted share awards | (182) | (5) |
| Payment of debt issuance cost | (150) | — |
| Proceeds from issuance of Series A and Series B Convertible Redeemable Preferred Stock, net of issuance costs | — | 22,468 |
| Redemption of Series A and Series B Convertible Redeemable Preferred Stock | — | (26,250) |
| Net cash provided by financing activities | 37,057 | 43,173 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 256 | (24,274) |
| Cash, cash equivalents and restricted cash at beginning of year | 14,555 | 38,829 |
| Cash, cash equivalents and restricted cash at end of year | $14,811 | $14,555 |
| Supplemental cash flow information: | ||
| Cash and cash equivalents | $14,473 | $14,217 |
| Restricted cash | 338 | 338 |
| Total cash, cash equivalents and restricted cash | $14,811 | $14,555 |
| Supplemental non-cash flow information: | ||
| Additions (deletions) to right-of-use lease assets in exchange for new or modifications to operating lease liabilities | $419 | $(77) |
| Deletions to operating lease liabilities obtained from new operating lease liabilities resulting from modification of original lease arrangement | $— | $(369) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.